Senotherapeutics

cells

Abstract

Cellular senescence is one of hallmarks of aging and accumulation of senescent cells with age contributes to tissue or organismal aging, as well as the pathophysiologies of diverse age-related diseases. Genetic ablation of senescent cells in tissues lengthened health span and reduced the risk of age-related pathologies in a mouse model, suggesting a direct link between senescent cells, longevity, and age-related diseases. Therefore, senotherapeutics, medicines targeting senescent cells, might be an emerging strategy for the extension of health span, and prevention or treatment of age-related diseases.

Senotherapeutics are classified as senolytics which kills senescent cells selectively; senomorphics which modulate functions and morphology of senescent cells to those of young cells, or delays the progression of young cells to senescent cells in tissues; and immune-system mediators of the clearance of senescent cells. Some senolytics and senomorphics have been proven to markedly prevent or treat age-related diseases in animal models.

This review will present the current status of the development of senotherapeutics, in relation to aging itself and age-related diseases. Finally, future directions and opportunities for senotherapeutics use will discussed. This knowledge will provide information that can be used to develop novel senotherapeutics for health span and age-related diseases.

FULL TEXT: BMB Reports